Yongsub Choi | Cardiovascular Disease | Best Researcher Award

Posted on 20/03/202520/03/2025 by Pencis

Dr. Yongsub Choi | Cardiovascular Disease | Best Researcher Award

Dr. Yongsub Choi, Bellin Memorial Hospital, South Korea

Dr. Yongsub Choi is a dedicated internal medicine physician at Bellin Memorial Hospital, Green Bay, WI. He completed his MBBS (Summa Cum Laude) from Harbin Medical University, China, and an Internal Medicine Residency at BronxCare Health System, NYC. With extensive research experience in cardiology, nephrology, and gastroenterology, he has contributed to advancements in ventricular arrhythmia, atrial fibrillation, and liver recovery. Dr. Choi’s diverse background includes leadership roles, international medical practice, and teaching. His commitment to patient care, research, and global healthcare improvement makes him a distinguished figure in the field of internal medicine.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Yongsub Choi’s academic journey is marked by excellence and dedication. He earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) from Harbin Medical University, China, graduating Summa Cum Laude. His academic excellence was evident throughout his studies, securing the First Prize Scholarship multiple times (2008-2009, 2011-2014). Prior to his medical education, he pursued Theology and Anthropology at Don Bosco Center of Studies, Manila, Philippines, where he graduated Cum Laude. Additionally, he completed his Bachelor of Philosophy (B.Ph) at Gwangju Catholic University, South Korea.

🏥PROFESSIONAL ENDEAVORS:

Dr. Choi has built a dynamic and diverse career in internal medicine, research, and leadership. Currently, he serves as a Hospitalist at the Department of Internal Medicine, Apogee Physicians, Bellin Memorial Hospital, Green Bay, WI (April 2023 – Present). His previous medical roles include:

Resident Physician at BronxCare Health System, NYC, USA (Feb 2020 – Jan 2023)
Locum Intern at Savanna-La-Mar Public General Hospital, Jamaica (Jan – June 2019)

In addition to his medical career, he held leadership roles such as:

Acting Executive Director (Apr 2007 – Feb 2008) at International Cooperational Technical High School, Yanji, China
English Teacher at Baosigao Technical High School, Taiwan
Assistant Parish Priest at Gurosamdong Parish, South Korea
Private Soldier in the Republic of Korea Army, Cheolwon, South Korea

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASE:

Dr. Choi’s contributions to medical research have significantly impacted the fields of cardiology, nephrology, and gastroenterology. His research roles include:

Research Assistant – First Affiliated Hospital of Harbin Medical University, China

Investigated modulation of activated astrocytes in the hypothalamus paraventricular nucleus to prevent ventricular arrhythmia during acute myocardial infarction (July 2019 – Jan 2020).
Explored sonodynamic therapy for atrial fibrillation (AF) using a rabbit model (Mar 2017 – June 2018).
Studied mesenchymal stem cells with enhanced Bcl-2 expression to improve liver recovery in hepatic cirrhosis (July 2014 – Feb 2017).

Research Scholar – Albert Einstein College of Medicine, Bronx, NY

Focused on nephrology-related research under Dr. Victor L. Schuster, M.D. (June 2018 – Dec 2018).

🌍IMPACT AND INFLUENCE:

Dr. Choi’s work bridges clinical practice, academia, and international healthcare initiatives. His contributions extend beyond medical practice to mentorship, leadership, and medical education. His experience in multiple countries (USA, China, Jamaica, Taiwan, South Korea, and the Philippines) highlights his global perspective on healthcare and medical research.

🏅ACADEMIC CITES AND HONORS:

Dr. Choi has received numerous awards and recognitions:
Graduated Summa Cum Laude – Harbin Medical University (2014)
First Prize Scholarship (Top Student) – Harbin Medical University (2008-09, 2011-14)
Secretary of Class of 2008 – Harbin Medical University (2012-2014)
Cum Laude – Don Bosco Center of Studies, Manila, Philippines (2001)

🚀LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Choi continues to shape the future of internal medicine and medical research. His extensive experience in cardiology, nephrology, and gastroenterology positions him as a key contributor to advancements in patient care and treatment methodologies. Moving forward, he aims to:

Enhance clinical excellence through evidence-based medicine.
Contribute to medical education and mentorship.
Advance research in cardiovascular and metabolic diseases.
Improve healthcare accessibility and quality in underprivileged regions.

🌟CONCLUSION:

Dr. Yongsub Choi’s journey is a testament to dedication, excellence, and global impact in internal medicine and research. His expertise in cardiology, nephrology, and gastroenterology has contributed to significant advancements in patient care. With a strong foundation in clinical practice, leadership, and education, he continues to inspire future medical professionals. His commitment to evidence-based medicine, mentorship, and international healthcare development reflects his passion for improving lives worldwide. As he moves forward, Dr. Choi remains a trailblazer in internal medicine, striving for innovation and excellence in patient care and medical research.

TOP NOTABLE PUBLICATION

Probability assessment of pulmonary embolism using clinical and laboratory variables in hospitalized patients: A single-center, retrospective observational study

Authors: Y. Choi, Yongsub; N. Prasai, Neeti; T. Bhatt, Tanushree; A. Latif, Amber; M. Khaja, Misbahuddin

Journal: Thrombosis Update

Year: 2024

Lingyan Chen | Cardiovascular Diseases | Best Researcher Award

Posted on 17/02/202517/02/2025 by Pencis

Dr. Lingyan Chen | Cardiovascular Diseases | Best Researcher Award

Dr. Lingyan Chen, Wenzhou Medical university, China

Dr. Lingyan Chen is an Associate Researcher at Wenzhou Medical University, China, specializing in mitochondrial quality control and disease pathogenesis. She holds a Ph.D. from Wenzhou Medical University (2019-2022) and completed a postdoctoral fellowship at Guangzhou Medical University (2019-2024). Her research focuses on gene knockout models, tumor studies, and cardiovascular pharmacology. She has received multiple awards, including honors from the Circulation Journal Awards (Japan) and the Zhejiang Society of Biochemistry. With extensive experience in molecular biology techniques, Dr. Chen continues to advance biomedical research, aiming to develop novel therapeutic strategies for metabolic and cardiovascular diseases.

AUTHOR PROFILE

Scopus Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Lingyan Chen embarked on her academic journey at Changsha Medical University, earning a B.Sc. degree (2006-2009). She then pursued a M.Sc. at The University of South China (USC) (2015-2018), where she focused on pathogenesis and prevention of atherosclerosis, supported by prestigious research grants. She completed her Ph.D. at Wenzhou Medical University (WMU) (2019-2022), concentrating on mitochondrial quality control and its implications for related diseases.

🏥PROFESSIONAL ENDEAVORS:

🔹 Guangzhou Medical University (Postdoctoral Researcher) (2019-2024) – Advanced research in mitochondrial pathogenesis and disease modeling.
🔹 Guangzhou Medical School (Assistant Professor) (2018) – Engaged in pharmacology research on cardiovascular diseases.
🔹 Guangzhou Medical University (Research Assistant) (2018) – Coordinated multi-institutional research projects and managed key laboratory operations.
🔹 The Second People’s Hospital of Changde (Pediatric Nurse) (2009-2015) – Provided clinical care for newborns and critically ill children, mentoring trainee nurses.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Dr. Chen’s research spans multiple domains in biomedical sciences, including:
✅ Mitochondrial Quality Control & Disease Mechanisms – Investigated gene knockout/knockin mice models, heterogeneous tumors, and disease modeling for liver cancer and diabetes.
✅ Cardiovascular Pharmacology – Conducted Western Blotting, qPCR, immunofluorescence, and genetic experiments on macrophage behavior.
✅ Atherosclerosis & Hypertriglyceridemia – Studied clinical patient data, serum sample analysis, and statistical evaluations to uncover disease mechanisms.

🌍IMPACT AND INFLUENCE:

Dr. Chen has significantly influenced mitochondrial pathogenesis and cardiovascular research, contributing valuable insights into gene expression, disease prevention, and targeted treatments. Her research findings have aided in therapeutic advancements, particularly in cardiovascular disorders and metabolic diseases.

📚ACADEMIC CITES & LEGACY:

Dr. Chen’s research has been published in top-tier scientific journals, earning citations in the fields of biochemistry, molecular biology, and cardiovascular medicine. Her work serves as a foundation for future studies in mitochondrial dysfunction and therapeutic innovations.

🚀FUTURE CONTRIBUTIONS & VISION:

As an Associate Researcher at Wenzhou Medical University (2025-Present), Dr. Chen continues her groundbreaking research in mitochondrial medicine and disease pathogenesis. She aims to:
🔹 Develop novel therapeutic strategies for cardiovascular and metabolic disorders.
🔹 Expand research on genetic and molecular mechanisms underlying disease progression.
🔹 Mentor the next generation of biomedical researchers and medical professionals.

🏆AWARDS AND HONORS:

🔹 2020 – Second Prize in the 16th Graduate Academic Competition, Wenzhou Medical University
🔹 2020 – Second Prize in the “Xinzhi” Youth Forum, Zhejiang Society of Biochemistry and Molecular Biology
🔹 2018 – Second Prize for Excellent Experimental Research Paper, Circulation Journal Awards (Japan)
🔹 2018 – Outstanding Communist of the University of South China
🔹 2017 – 3rd Prize, Young Investigator Oral Presentation, 14th National Conference on Atherosclerotic Diseases & China-Canada Symposium
🔹 2017 – Excellence Award, Young Investigator Oral Presentation, Cross-Strait Cardiovascular Science Symposium
🔹 2017 – 1st Scholarship, University of South China
🔹 2016 – 2nd Scholarship, University of South China
🔹 2015 – 2nd Scholarship, University of South China

🌟CONCLUSION:

Dr. Lingyan Chen’s dedication to biomedical research, particularly in mitochondrial quality control and cardiovascular pharmacology, has significantly contributed to understanding disease mechanisms and potential treatments. Her extensive experience in molecular biology, combined with numerous accolades and publications, underscores her impact in the scientific community. As she continues her research at Wenzhou Medical University, Dr. Chen remains committed to advancing medical science, mentoring future researchers, and developing innovative therapeutic strategies. Her work holds great promise for improving treatments for metabolic and cardiovascular diseases, making her a valuable figure in the field of biomedical research.

TOP NOTABLE PUBLICATIONS

Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis

Authors: Chen, Lingyan; Chen, Dejian; Pan, Yiming; Zhang, Dawei; Xia, Xiaodan

Journal: Cell Death and Disease

Year: 2024

Ciclopirox drives growth arrest and autophagic cell death through STAT3 in gastric cancer cells

Authors: Chen, Lingyan; Chen, Dejian; Li, Jiwei; Lu, Xiaoang; Lu, Bin

Journal: Cell Death and Disease

Year: 2022

MicroRNA-377 inhibits atherosclerosis by regulating triglyceride metabolism through the DNA methyltransferase 1 in apolipoprotein E-knockout mice

Authors: Chen, Lingyan (First Author); Xia, Xiaodan; Zhao, Zhiwei; Gong, Dan; Ma, Xuefeng; Yu, Xuhui; Zhang, Qi; Wang, Shengqi; Dai, Xinyu; Zheng, Xianliang; Zhang, Dawei; Yin, Wende; Tang, ChaoKun

Journal: Circulation Journal

Year: 2018

Myocardin suppression increases lipid retention and atherosclerosis via downregulation of ABCA1 in vascular smooth muscle cells

Authors: Xia, Xiaodan; Yu, Xuhui; Chen, Lingyan (Co-first Author); Xie, Shuo; Feng, Yan; Yang, Rui; Zhao, Zhiwei; Li, Hui; Wang, Gang; Tang, ChaoKun

Journal: Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids

Year: 2021

Heart shock protein 70 accelerates atherosclerosis by downregulating the expression of ABCA1 and ABCG1 through the JNK/Elk-1 pathway

Authors: Zhao, Zhiwei; Zhang, Min; Chen, Lingyan (Co-first Author); Gong, Dan; Xia, Xiaodan; Yu, Xuhui; Wang, Shengqi; Ou, Xue; Dai, Xinyu; Zheng, Xianliang; Zhang, Dawei; Tang, ChaoKun

Journal: Biochimica et Biophysica Acta

Year: 2018

Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages

Authors: Li, ChaoHui; Gong, Dan; Chen, Lingyan (Co-first Author); Zhang, Min; Xia, Xiaodan; Cheng, Hongping; Huang, Chen; Zhao, Zhiwei; Zheng, Xianliang; Tang, XueEr; Tang, ChaoKun

Journal: European Journal of Pharmacology

Year: 2017

IL-8 negatively regulates ABCA1 expression and cholesterol efflux via upregulating miR-183 in THP-1 macrophage-derived foam cells

Authors: Tang, XueEr; Li, Hui; Chen, Lingyan (Co-first Author); Xia, Xiaodan; Zhao, Zhiwei; Zheng, Xianliang; Zhao, GuoJun; Tang, ChaoKun

Journal: Cytokine

Year: 2019

Qian-Qian chen | Pharmacology | Best Researcher Award

Posted on 26/12/202426/12/2024 by Pencis

Prof. Qian-Qian chen | Pharmacology | Best Researcher Award

Prof. Qian-Qian chen, Nanjing University of Chinese Medicine, China

Prof. Qian-Qian Chen is an Associate Professor at the School of Pharmacy at Nanjing University of Chinese Medicine, China. He holds a Ph.D. in Pharmacognosy from China Pharmaceutical University, Nanjing. His research focuses on the molecular mechanisms of cardiovascular and renal diseases, the regulatory effects of traditional Chinese medicine (TCM) on disease progression, and the role of the neuraminidase protein family in chronic conditions. Prof. Chen has published extensively in high-impact journals such as Advanced Science, Nature Communications, and European Heart Journal. He is committed to advancing both modern pharmacology and TCM in the context of chronic diseases.

Author Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Qian-Qian Chen began his academic journey with a Bachelor of Science in Pharmacy from Beihua University, Jilin, China, graduating in June 2015. Demonstrating exceptional academic potential, he pursued a Master’s degree in Pharmacy at China Pharmaceutical University, Nanjing, China, from September 2015 to July 2018. He further refined his expertise by completing a Ph.D. in Pharmacognosy at the same university, achieving his doctorate in July 2021.

🏫PROFESSIONAL ENDEAVORS:

Currently serving as an Associate Professor and Master’s Supervisor in Pharmacology at the School of Pharmacy, Nanjing University of Chinese Medicine, Prof. Chen has been in this role since March 2022. His teaching and mentorship significantly contribute to nurturing the next generation of researchers in pharmacology and traditional Chinese medicine (TCM).

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Pharmacology:

Prof. Chen’s research is primarily centered around the molecular mechanisms underlying cardiovascular and renal diseases. His work focuses on three major areas:
1️⃣ Exploring the molecular pathways involved in cardiovascular and renal disease progression.
2️⃣ Investigating the regulatory effects of traditional Chinese medicine (TCM) on these diseases.
3️⃣ Unveiling the roles and mechanisms of the neuraminidase protein family in chronic conditions, including ventricular remodeling and chronic kidney injury.

His dedication to these fields has yielded a wealth of insights that advance understanding and treatment strategies for complex cardiorenal syndromes.

📈IMPACT AND INFLUENCE:

Prof. Chen has made significant contributions to the scientific community through his publications in prestigious journals. These include:

Advanced Science (2024)
Nature Communications (2023)
European Heart Journal (2021)
Journal of Ethnopharmacology (2021)
The American Journal of Chinese Medicine (2021)
Circulation (2018)

His groundbreaking studies on cardiovascular and renal diseases have been highly cited and praised for their clinical relevance and innovative methodologies.

📚ACADEMIC CITES AND LEGACY:

Prof. Chen’s published work has been widely referenced in the fields of pharmacology, traditional Chinese medicine, and chronic disease research. His studies, particularly those addressing the interplay between cardiovascular and renal systems, serve as a cornerstone for researchers exploring related domains.

🌟FUTURE CONTRIBUTIONS AND VISION:

Looking ahead, Prof. Chen aims to:

Expand the understanding of traditional Chinese medicine’s regulatory roles in disease mechanisms.
Advance therapeutic strategies for chronic diseases through interdisciplinary research.
Mentor emerging researchers, fostering innovation and excellence in pharmacological sciences.

His commitment to merging modern scientific techniques with traditional medicine holds the promise of revolutionary breakthroughs in healthcare.

🌍CONCLUSION:

Prof. Qian-Qian Chen’s impressive academic trajectory, impactful research, and dedication to advancing pharmacology place him as a leading figure in his field. His work not only bridges the gap between traditional and modern medicine but also sets a foundation for transformative discoveries that will benefit patients worldwide.

Top Notable Publications:

Targeting Neuraminidase 4 Attenuates Kidney Fibrosis in Mice

Authors: Qian-Qian Chen

Journal: Advanced Science

Year: 2024

DOI: 10.1002/advs.202406936

Neuraminidase 1 is a Driver of Experimental Cardiac Hypertrophy

Authors: Qian-Qian Chen

Journal: European Heart Journal

Year: 2021

DOI: 10.1093/eurheartj/ehab347

Neuraminidase 1 and its Inhibitors from Chinese Herbal Medicines: An Emerging Role for Cardiovascular Diseases

Authors: Qian-Qian Chen

Journal: The American Journal of Chinese Medicine

Year: 2021

DOI: 10.1142/s0192415x21500403

PMID: 33827385

Untargeted Metabolomics and Lipidomics Uncovering the Cardioprotective Effects of Huanglian Jiedu Decoction on Pathological Cardiac Hypertrophy and Remodeling

Authors: Qian-Qian Chen

Journal: Journal of Ethnopharmacology

Year: 2020

DOI: 10.1016/j.jep.2020.113646

PMID: 33264659

Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases

Authors: Qian-Qian Chen

Journal: Circulation

Year: 2017

DOI: 10.1161/circulationaha.117.031139

PMID: 29212895

Mincai li | vascular calcification | Best Researcher Award

Posted on 26/12/202426/12/2024 by Pencis

Prof. Dr. Mincai li | vascular calcification | Best Researcher Award

Prof. Dr. Mincai li, Hubei University of Science and Technology, China

Prof. Dr. Mincai Li is a distinguished academic at Hubei University of Science and Technology, China. He holds an MD and Master’s degree in Pathology and Pathophysiology from Huazhong University of Science and Technology. With extensive experience in teaching, Prof. Li has served as a Professor since 2017, after roles as Associate Professor and Lecturer at the same institution. His research focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has published over 40 scientific papers, including 15 SCI-indexed articles, and has received multiple awards for his scientific and teaching contributions.

Author Profile

Scopus Profile

🎓 Education Background:

Prof. Dr. Mincai Li completed his MD in Pathology and Pathophysiology at Huazhong University of Science and Technology (2007-2010), graduating in the top 10% of his class. He also earned his Master’s in Pathology and Pathophysiology from the same institution (2004-2007), ranking in the top 10%. Prior to that, he obtained a Bachelor’s in Clinical Medicine from Hubei University of Science and Technology (1993-1998), where he was in the top 30% of his cohort.

💼 Professional Experience:

Prof. Dr. Mincai Li has an extensive academic career at Hubei University of Science and Technology, where he has held progressively senior roles. Since January 2017, he has served as a Professor, following his tenure as Associate Professor from January 2012 to December 2016. From July 2010 to December 2011, he was a Lecturer, and earlier in his career, he worked as a Teaching Assistant from July 1998 to August 2004. Throughout his tenure, Prof. Dr. Li has contributed significantly to education and research in his field, shaping the academic environment at the university.

🩺 Medical Education & Teaching:

Prof. Dr. Mincai Li has made significant contributions to medical education, primarily teaching Pathology and Oral Histopathology courses. He has played a leading role in three provincial teaching research projects within Hubei’s higher education institutions, demonstrating his commitment to advancing academic standards. His exceptional teaching efforts have been recognized with awards, including a second prize and a third prize for teaching achievements at Hubei University of Science and Technology. Prof. Dr. Li’s dedication to both education and research has made a lasting impact on the academic community and the development of future medical professionals.

🔬 Scientific Research:

Prof. Dr. Mincai Li’s research primarily focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has led and contributed to 10 national, provincial, and municipal research projects, showcasing his expertise in these critical areas. Prof. Li has published over 40 scientific papers, including 15 SCI-indexed articles, and has edited a textbook. His significant contributions to scientific research have earned him recognition, including a second prize and a third prize for scientific and technological progress in Xianning City. His work continues to advance the understanding of critical medical conditions and therapeutic approaches.

🏅 Achievements and Honors:

Prof. Dr. Mincai Li has earned several prestigious awards throughout his career. In 2015, he was honored with the Second and Third Prizes for Science and Technology Progress in Xianning City, recognizing his contributions to scientific advancement. In 2016, he received both the Second and Third Prizes for Teaching Achievements at Hubei Institute of Science and Technology, highlighting his dedication to education. That same year, Prof. Li was awarded the Third Prize for the Second Natural Science Outstanding Academic Achievement Thesis Award in Xianning City, further acknowledging his impactful research and academic excellence. These accolades reflect his commitment to both teaching and scientific progress.

🌟Conclusion:

Prof. Dr. Mincai Li is a highly accomplished academic and researcher at Hubei University of Science and Technology, China. With a strong background in Pathology and Pathophysiology, he has made significant contributions to both education and scientific research. His work on atherosclerosis and glioma drugs has earned him national and regional recognition. As a dedicated professor, he has shaped the academic development of many students, while his research continues to advance medical science. Prof. Li’s numerous awards and honors reflect his unwavering commitment to excellence in both teaching and research.

Top Notable Publications:

Target analysis and identification of curcumin against vascular calcification

Authors: Li, Q., Zhou, Q., Li, S., Li, M., Xia, H.

Journal: Scientific Reports

Year: 2024

The causal relationship between thoracic aortic aneurysm and immune cells: a mendelian randomization study

Authors: Liu, G., Pan, S., Xia, H., Li, M., Wu, A.

Journal: BMC Cardiovascular Disorders

Year: 2024

Attenuating Atherosclerosis through Inhibition of the NF-κB/NLRP3/IL-1β Pathway-Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Cardiovascular Therapeutics

Year: 2024

Identification of key genes and pathways in atherosclerosis using integrated bioinformatics analysis

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: BMC Medical Genomics

Year: 2023

Bioinformatic Identification of the Pyroptosis-Related Transcription Factor-MicroRNA-Target Gene Regulatory Network in Angiotensin II-Induced Cardiac Remodeling and Validation of Key Components

Authors: Huang, T., Ding, J., Lin, L., Yu, L., Li, M.

Journal: Frontiers in Bioscience (Landmark edition)

Year: 2023

Increased Neuromedin B is Associated with a Favorable Prognosis in Glioblastoma

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Frontiers in Bioscience – Landmark

Year: 2023

Study on mechanism of resveratrol regulation of NLRP3 mediated pyroptosis of vascular smooth muscle cells resistance to atherosclerosis

Authors: Li, S., Li, Q., Zhou, C., Ouyang, C., Li, M.

Journal: Drug Evaluation Research

Year: 2022

Curcumin suppresses glioblastoma cell proliferation by p-AKT/mTOR pathway and increases the PTEN expression

Authors: Wang, Z., Liu, F., Liao, W., Li, M., Xia, H.

Journal: Archives of Biochemistry and Biophysics

Year: 2020

Captopril Attenuates the Upregulated Connexin 43 Expression in Artery Calcification

Authors: Li, M., Wang, Z., Shao, J., Yu, L., Hu, Z.

Journal: Archives of Medical Research

Year: 2020

XIngcheng Yi | Myocardial tissue repair | Best Researcher Award

Posted on 28/11/202428/11/2024 by Pencis

Dr. XIngcheng Yi | Myocardial tissue repair | Best Researcher Award

Dr. XIngcheng Yi, The First Hospital of Jilin University, China

🌟Profile Overview:

Dr. Xingcheng Yi is a distinguished medical professional at The First Hospital of Jilin University, China, specializing in cutting-edge clinical and translational research. With a strong focus on advancing patient care, Dr. Yi’s expertise spans cardiovascular medicine, oncology, and innovative therapeutic approaches. A dedicated scholar and practitioner, Dr. Yi is actively involved in groundbreaking studies, contributing to the global medical community through peer-reviewed publications and collaborative projects. Known for integrating clinical insights with advanced research, Dr. Yi’s work continues to impact healthcare practices and improve outcomes for patients worldwide.

Profile:

Scopus Profile

🎓Current Position:

Currently serving as a lead researcher in Cell Biology, my work focuses on innovative therapeutic strategies for myocardial tissue repair. Leveraging expertise in computational biology, I aim to bridge experimental and computational sciences to drive impactful discoveries in cardiovascular health.

📚Academic Background:

Earned a Ph.D. in Cell Biology, with a thesis focused on molecular interaction networks in myocardial injury.
Prior to this, completed a Master’s in Biological Sciences, specializing in cellular mechanisms and computational applications.

📝Publications Achievements:

Publications: Authored 11 peer-reviewed journal articles, indexed in SCI and Scopus, spanning myocardial repair, single-cell transcriptomics, and graph deep learning.
Books: Published 11 books with ISBN registration, contributing to knowledge dissemination in cell biology and computational techniques.
Citations: Achieved a citation index of 18, demonstrating the growing influence of my research in the academic community.
Recognized for a recent impactful study on Ginsenoside Rb1 and PRDX6 in mitigating myocardial injury.

🔬Ongoing Research Projects:

Current Projects: Actively involved in three research projects, focusing on:

Synergistic Therapies: Examining natural compounds and molecular interactions for cardiac protection.
Transcriptomics: Exploring gene expression changes linked to tissue repair and cellular stress responses.
Graph-Based Models: Developing AI-based models to predict molecular interaction networks and their biological implications.

Collaborations: Engaged in interdisciplinary collaborations with computational scientists and clinical researchers to validate models in vivo.

🔍Research Interests:

Areas of expertise and passion include:

Myocardial Tissue Repair: Exploring cellular mechanisms to improve heart regeneration.
Single-Cell Transcriptomics: Unraveling cellular diversity and gene expression.
Graph Deep Learning: Applying cutting-edge computational tools for network analysis.
Bioinformatics: Leveraging data-driven approaches to solve biological challenges.

🏆Awards and Scholarships:

Recipient of multiple awards for research excellence, including the prestigious Best Researcher Award for groundbreaking work in myocardial repair.
Secured competitive scholarships during doctoral studies, highlighting academic rigor and potential.

🎤Professional Associations:

Active member of professional societies like the Society for Computational Biology and the American Heart Association, contributing to global discussions on translational research.

🎓Training & Workshops:

Participated in numerous workshops on advanced computational techniques, transcriptomics, and bioinformatics.
Conducted training sessions for peers, fostering skills in RNA-seq analysis and molecular modeling.

🧪Laboratory Experience and Publications:

Proficient in wet lab techniques such as immunohistochemistry, PCR, and cell culture, complemented by computational methods like network analysis and deep learning models.
Authored comprehensive reports and proposals that secured funding for cutting-edge research.

🛠️Tasks Completed as a Researcher:

Designed and executed experiments involving RNA sequencing and gene expression profiling.
Supervised lab teams in handling complex protocols for tissue repair studies.
Published high-impact manuscripts, showcasing methodological rigor and innovative findings.

🎤Oral Presentations:

Delivered over 15 oral presentations at national and international conferences, including keynote sessions on myocardial repair strategies.
Topics included novel therapeutic combinations and advancements in single-cell analysis.

🌟Success Factors:

My success stems from a combination of interdisciplinary expertise, strong analytical skills, and an unwavering commitment to advancing cardiovascular science.
Emphasis on collaboration ensures that my research remains globally relevant and impactful.

🌍Conclusion:

My journey as a researcher is defined by a relentless drive to innovate in myocardial tissue repair and computational biology. By integrating biological insights with computational tools, I aim to pave the way for new therapeutic solutions that save lives. From groundbreaking publications to collaborative projects, my work continues to contribute meaningfully to science and society.

Top Notable Publications:

Article: Hypoxia adaptation mechanism in rats’ peripheral auditory system in high altitude migration: a time series transcriptome analysis
Authors: Wang, L., Yi, X., Zhou, Y., Su, X., Wang, P.
Year: 2024
Journal: Scientific Reports
Citations: 0

Letter: Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study
Authors: Zhang, Y., Liang, X., Xu, W., Dai, Y., Jin, F.
Year: 2024
Journal: Journal of Hematology and Oncology
Citations: 1

Article: Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis
Authors: Xu, W., Liang, X., Liu, S., Dai, Y., Jin, F.
Year: 2024
Journal: Clinical Medicine, Journal of the Royal College of Physicians of London
Citations: 0

Article: Plumbagin induces G2/M arrest and apoptosis and ferroptosis via ROS/p38 MAPK pathway in human osteosarcoma cells
Authors: Li, J., Gao, H., Wang, P., Zhang, Y., Li, S.
Year: 2024
Journal: Alexandria Engineering Journal
Citations: 1

Article: MediDRNet: Tackling category imbalance in diabetic retinopathy classification with dual-branch learning and prototypical contrastive learning
Authors: Teng, S., Wang, B., Yang, F., Zhang, X., Sun, Y.
Year: 2024
Journal: Computer Methods and Programs in Biomedicine
Citations: 0

Article in Press: Synergistic effects of ginsenoside Rb1 and peroxiredoxin 6 in enhancing myocardial injury treatment through anti-inflammatory, anti-oxidative, and anti-apoptotic mechanisms
Authors: Mu, R., Li, Y., Cui, Y., Guo, X., Yi, X.
Year: 2024
Journal: Journal of Ginseng Research
Citations: 0

Letter: More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma
Authors: Tian, M., Liang, X., Xu, W., Dai, Y., Jin, F.
Year: 2023
Journal: Annals of Hematology
Citations: 0

Letter: Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma
Authors: Yang, P., Xu, W., Liang, X., Dai, Y., Jin, F.
Year: 2023
Journal: American Journal of Hematology
Citations: 3

Article: Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
Authors: Yang, P., Chen, H., Liang, X., Dai, Y., Jin, F.
Year: 2023
Journal: American Journal of Hematology
Citations: 7

Article: Research on the pathological mechanism of rectal adenocarcinoma based on DNA methylation
Authors: Pan, X., Yi, X., Lan, M., Zhou, F., Wu, W.
Year: 2023
Journal: Medicine (United States)
Citations: 2

Paweł Rajewski | Cardiovascular risk | Best Research Article Award | Best Research Article Award

Posted on 11/11/202411/11/2024 by Pencis

Prof Dr. Paweł Rajewski | Cardiovascular risk | Best Research Article Award

Prof Dr. Paweł Rajewski, WSOZ, Poland

🌟Bioinformatics:

Prof. Dr. Paweł Rajewski is a leading expert in internal medicine, infectious diseases, hepatology, and clinical transplantation. Serving as the Rector of the Faculty of Health Sciences at the University of Health Sciences in Bydgoszcz, Poland, he is also the Provincial Consultant in Infectious Diseases for the Kuyavian-Pomeranian Voivodeship. In addition, he heads both the Department of Internal Medicine and Infectious Diseases at Tadeusz Browicz Provincial Infectious Disease Hospital and the Liver, Internal, Infectious, and Metabolic Disorders Clinic at CM Gizińscy in Bydgoszcz. Dr. Rajewski is a certified lipidologist and obesitologist, with over 200 published articles focusing on metabolic disorders, liver diseases, and cardiovascular health. He is also the founder of the Dr. Rajewski Foundation, which supports research and education in health sciences.

Profile:

Orcid Profile

🏥Current Position and Roles:

Dr. Paweł Rajewski is a distinguished medical doctor, professor, and the rector of the Faculty of Health Sciences at the University of Health Sciences in Bydgoszcz. He holds the vital role of Provincial Consultant in Infectious Diseases for the Kuyavian-Pomeranian Voivodeship, providing oversight and strategic insights on infectious disease management in the region. Dr. Rajewski serves as the Head of the Department of Internal Medicine and Infectious Diseases at the Tadeusz Browicz Provincial Infectious Disease Hospital in Bydgoszcz, as well as the Head of the Liver, Internal, Infectious, and Metabolic Disorders Clinic at CM Gizińscy in Bydgoszcz. Previously, he served as the Medical Director and Head of the Department of Internal Medicine and Hepatology at the Emil Warmiński Multispecialist City Hospital. Through these roles, he contributes to the health of countless patients while also shaping medical policy and practice.

🎓Academic Background:

Dr. Rajewski’s academic journey has been marked by an enduring commitment to medicine, specializing in areas such as internal medicine, infectious diseases, hepatology, and clinical transplantation. His qualifications in these areas form the bedrock of his clinical and academic expertise, enabling him to deliver high-impact research and patient care in fields that are central to public health. Dr. Rajewski’s education includes specialty certifications as a lipidologist, accredited by the Polish Lipid Association, and an obesitologist with certifications from the Polish Association for the Study of Obesity and the Polish Society for Obesity Treatment.

📚Research Interests and Publication Achievements:

Dr. Rajewski has contributed over 200 articles, primarily focused on metabolic disorders, obesity, liver diseases, and cardiovascular risk factors. His work, published in reputed medical journals, has been instrumental in advancing knowledge on these critical health issues. His research sheds light on complex metabolic processes, influencing both preventive and therapeutic approaches to conditions like non-alcoholic fatty liver disease and atherosclerosis. His publications are widely recognized for their scientific rigor and relevance, contributing to his esteemed reputation in the medical research community.

🔬Ongoing Research Projects:

Dr. Rajewski is currently engaged in various research projects that address emerging concerns in metabolic health and infectious diseases. His work on liver disease mechanisms and cardiovascular risk factors associated with obesity and metabolic syndrome aims to uncover better diagnostic markers and treatment pathways. A recent focus involves studying COVID-19’s impact on liver function and the interplay between viral infections and metabolic health, topics highly relevant in today’s healthcare landscape.

👥Professional Associations and Certifications:

Dr. Rajewski’s memberships in prestigious medical associations, including the Polish Lipid Association and the Polish Association for the Study of Obesity, underscore his dedication to staying at the forefront of medical science. His certified expertise as a lipidologist and obesitologist enables him to approach health issues with a comprehensive understanding of lipid and metabolic disorders, enhancing the efficacy of treatments and preventive measures.

🏆Scholarships and Awards:

Dr. Rajewski’s contributions to medicine have earned him numerous accolades, recognizing his achievements in research and clinical practice. These awards celebrate his innovation in metabolic research and his pivotal role in infectious disease management. His scholarship funding reflects a legacy of excellence and a commitment to advancing medical science.

📖Training & Workshops Attended:

In his pursuit of continual growth, Dr. Rajewski has attended a series of specialized workshops on bioinformatics, advanced diagnostics, and clinical applications in infectious disease management. These workshops equip him with cutting-edge skills that he applies to his daily work, benefiting patients and enhancing the training of his medical students.

💻Contributions to Bioinformatics and Clinical Research:

A proficient bioinformatician, Dr. Rajewski integrates data science and computational tools in his research on metabolic diseases and infectious pathogens. By utilizing bioinformatics, he has been able to analyze complex datasets, leading to insights into genetic predispositions and disease progression. His ability to harness bioinformatics tools strengthens his work in both metabolic and infectious disease studies, positioning him at the cutting edge of medical research.

🎤Oral Presentations and Conferences:

As a frequent presenter at national and international conferences, Dr. Rajewski shares his research findings with the medical community. His presentations cover topics like liver disease pathogenesis, metabolic syndrome treatments, and emerging infectious diseases. He contributes actively to knowledge exchange, with his lectures serving as valuable learning resources for both peers and students.

📊Key Tasks and Responsibilities as a Researcher:

In his research role, Dr. Rajewski coordinates multi-disciplinary teams, designing studies, and conducting extensive data analyses. His responsibilities include overseeing clinical trials and ensuring the ethical integrity of research protocols. His dedication to stringent research standards has led to significant findings that improve patient care protocols and inform public health strategies.

🌠Success Factors:

Dr. Rajewski attributes his success to his commitment to continuous learning, innovation, and collaboration. His ability to bridge theoretical research with practical applications in healthcare makes his contributions exceptionally valuable. Additionally, his leadership in the clinical setting exemplifies his holistic approach to healthcare, balancing research with direct patient care.

🔍Publications & Laboratory Experience:

Dr. Rajewski’s extensive laboratory experience includes advanced diagnostics in liver diseases, where he employs innovative techniques to diagnose and manage conditions like hepatitis and liver fibrosis. His publications detail his findings on the effectiveness of new biomarkers, offering insights that enhance both diagnostics and treatment options for liver and metabolic disorders.

🌐Conclusion:

Dr. Paweł Rajewski’s career exemplifies a dedication to excellence in medicine, research, and public health. His multifaceted expertise in internal medicine, infectious diseases, and metabolic health has propelled him to the forefront of healthcare in Poland. Dr. Rajewski’s contributions are invaluable to the fields of hepatology and infectious disease, positively impacting patient care and advancing medical knowledge. Through his foundation, research, and clinical roles, he continues to shape the future of health sciences, creating a lasting legacy of compassion, knowledge, and innovation.

Top Notable Publications:

Hepatitis C Infection Is Not a Cardiovascular Risk Factor in Young Adults